IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype.
Biomarker
GBP1
Immunotherapy
Tumor microenvironment
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
24
01
2024
accepted:
09
03
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
Immunotherapy is widely used in cancer treatment; however, only a subset of patients responds well to it. Significant efforts have been made to identify patients who will benefit from immunotherapy. Successful anti-tumor immunity depends on an intact cancer-immunity cycle, especially long-lasting CD8
Identifiants
pubmed: 38758367
doi: 10.1007/s10238-024-01328-w
pii: 10.1007/s10238-024-01328-w
doi:
Substances chimiques
GBP1 protein, human
0
IL15 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Subventions
Organisme : National Natural Science Foundation of China
ID : 82073147
Organisme : National Natural Science Foundation of China
ID : 62131009, 82072597
Informations de copyright
© 2024. The Author(s).
Références
Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1195–204. https://doi.org/10.1001/jamaoncol.2019.1549 .
doi: 10.1001/jamaoncol.2019.1549
pubmed: 31318407
pmcid: 6646995
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/NEJMoa1507643 .
doi: 10.1056/NEJMoa1507643
pubmed: 26412456
pmcid: 5705936
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709–17. https://doi.org/10.1001/jamaoncol.2021.0366 .
doi: 10.1001/jamaoncol.2021.0366
pubmed: 33792623
pmcid: 8017481
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403. https://doi.org/10.1016/j.ccell.2023.02.016 .
doi: 10.1016/j.ccell.2023.02.016
pubmed: 36917948
Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209–23. https://doi.org/10.1038/s41577-021-00574-3 .
doi: 10.1038/s41577-021-00574-3
pubmed: 34253904
Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J Immunol. 2018;200:432–42. https://doi.org/10.4049/jimmunol.1701269 .
doi: 10.4049/jimmunol.1701269
pubmed: 29311385
Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu YX. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;30:500. https://doi.org/10.1016/j.ccell.2016.08.011 .
doi: 10.1016/j.ccell.2016.08.011
pubmed: 27622338
Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17–35. https://doi.org/10.1016/j.immuni.2019.12.011 .
doi: 10.1016/j.immuni.2019.12.011
pubmed: 31940268
Liang Y, Hannan R, Fu YX. Type I IFN activating type I dendritic cells for antitumor immunity. Clin Cancer Res. 2021;27:3818–24. https://doi.org/10.1158/1078-0432.CCR-20-2564 .
doi: 10.1158/1078-0432.CCR-20-2564
pubmed: 33692027
St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30:695–704. https://doi.org/10.1016/j.tcb.2020.06.003 .
doi: 10.1016/j.tcb.2020.06.003
pubmed: 32624246
Raeber ME, Zurbuchen Y, Impellizzieri D, Boyman O. The role of cytokines in T-cell memory in health and disease. Immunol Rev. 2018;283:176–93. https://doi.org/10.1111/imr.12644 .
doi: 10.1111/imr.12644
pubmed: 29664568
Nolz JC, Richer MJ. Control of memory CD8(+) T cell longevity and effector functions by IL-15. Mol Immunol. 2020;117:180–8. https://doi.org/10.1016/j.molimm.2019.11.011 .
doi: 10.1016/j.molimm.2019.11.011
pubmed: 31816491
Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et al. Distinct Immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35(238–255):e236. https://doi.org/10.1016/j.ccell.2019.01.003 .
doi: 10.1016/j.ccell.2019.01.003
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916–27. https://doi.org/10.1038/s41591-019-0654-5 .
doi: 10.1038/s41591-019-0654-5
pubmed: 31792460
pmcid: 6898788
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman WH, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(934–949):e916. https://doi.org/10.1016/j.cell.2017.09.028 .
doi: 10.1016/j.cell.2017.09.028
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. https://doi.org/10.1126/science.aad0095 .
doi: 10.1126/science.aad0095
pubmed: 26359337
pmcid: 5054517
Song Q, Hawkins GA, Wudel L, Chou PC, Forbes E, Pullikuth AK, Liu L, Jin G, Craddock L, Topaloglu U, et al. Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. Cancer Med. 2019;8:3072–85. https://doi.org/10.1002/cam4.2113 .
doi: 10.1002/cam4.2113
pubmed: 31033233
pmcid: 6558497
Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, et al. A Cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(984–997):e924. https://doi.org/10.1016/j.cell.2018.09.006 .
doi: 10.1016/j.cell.2018.09.006
Nieto P, Elosua-Bayes M, Trincado JL, Marchese D, Massoni-Badosa R, Salvany M, Henriques A, Nieto J, Aguilar-Fernandez S, Mereu E, et al. A single-cell tumor immune atlas for precision oncology. Genome Res. 2021;31:1913–26. https://doi.org/10.1101/gr.273300.120 .
doi: 10.1101/gr.273300.120
pubmed: 34548323
pmcid: 8494216
Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25. https://doi.org/10.1016/j.cels.2015.12.004 .
doi: 10.1016/j.cels.2015.12.004
pubmed: 26771021
pmcid: 4707969
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50. https://doi.org/10.1073/pnas.0506580102 .
doi: 10.1073/pnas.0506580102
pubmed: 16199517
pmcid: 1239896
Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7 .
doi: 10.1186/1471-2105-14-7
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127:2930–40. https://doi.org/10.1172/JCI91190 .
doi: 10.1172/JCI91190
pubmed: 28650338
pmcid: 5531419
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76. https://doi.org/10.1016/S0140-6736(16)32455-2 .
doi: 10.1016/S0140-6736(16)32455-2
pubmed: 27939400
Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36:61–7. https://doi.org/10.1200/JCO.2017.74.9846 .
doi: 10.1200/JCO.2017.74.9846
pubmed: 29116900
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46. https://doi.org/10.1016/S0140-6736(16)00587-0 .
doi: 10.1016/S0140-6736(16)00587-0
pubmed: 26970723
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23. https://doi.org/10.1016/j.cell.2017.01.017 .
doi: 10.1016/j.cell.2017.01.017
pubmed: 28187290
pmcid: 5391692
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652–69. https://doi.org/10.1016/j.cell.2023.03.006 .
doi: 10.1016/j.cell.2023.03.006
pubmed: 37059068
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R. Comprehensive integration of single-cell data. Cell. 2019;177(1888–1902):e1821. https://doi.org/10.1016/j.cell.2019.05.031 .
doi: 10.1016/j.cell.2019.05.031
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8 .
doi: 10.1186/s13059-014-0550-8
pubmed: 25516281
pmcid: 4302049
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141. https://doi.org/10.1016/j.xinn.2021.100141 .
doi: 10.1016/j.xinn.2021.100141
pubmed: 34557778
pmcid: 8454663
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52. https://doi.org/10.1016/S1470-2045(17)30074-8 .
doi: 10.1016/S1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Honkala AT, Tailor D, Malhotra SV. Guanylate-binding protein 1: an emerging target in inflammation and cancer. Front Immunol. 2019;10:3139. https://doi.org/10.3389/fimmu.2019.03139 .
doi: 10.3389/fimmu.2019.03139
pubmed: 32117203
Chu H, Jin Z, Cheng JN, Jia Q, Zhu B, Cai H. Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy. Theranostics. 2023;13:1443–53. https://doi.org/10.7150/thno.81350 .
doi: 10.7150/thno.81350
pubmed: 36923532
pmcid: 10008737
Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, Chen Z, Zhang J, Hu Y, Yuan J, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13:4851. https://doi.org/10.1038/s41467-022-32570-z .
doi: 10.1038/s41467-022-32570-z
pubmed: 35982052
pmcid: 9388563
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022. https://doi.org/10.1172/JCI159579 .
doi: 10.1172/JCI159579
pubmed: 36099049
pmcid: 9621145
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022;17:1335–54. https://doi.org/10.1016/j.jtho.2022.09.109 .
doi: 10.1016/j.jtho.2022.09.109
pubmed: 36184066
House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26:487–504. https://doi.org/10.1158/1078-0432.CCR-19-1868 .
doi: 10.1158/1078-0432.CCR-19-1868
pubmed: 31636098
Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(885–900):e810. https://doi.org/10.1016/j.ccell.2019.05.004 .
doi: 10.1016/j.ccell.2019.05.004
Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(711–723):e714. https://doi.org/10.1016/j.ccell.2017.04.003 .
doi: 10.1016/j.ccell.2017.04.003
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. https://doi.org/10.1056/NEJMoa1606774 .
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–104. https://doi.org/10.1056/NEJMoa1801946 .
doi: 10.1056/NEJMoa1801946
pubmed: 29658845
pmcid: 7193684
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633–41. https://doi.org/10.1200/JCO.2017.75.3384 .
doi: 10.1200/JCO.2017.75.3384
pubmed: 29337640
pmcid: 6075848
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O’Neil BH, Mehnert JM, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318–27. https://doi.org/10.1200/JCO.2018.78.2276 .
doi: 10.1200/JCO.2018.78.2276
pubmed: 30557521
McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87–103. https://doi.org/10.1038/nri3787 .
doi: 10.1038/nri3787
pubmed: 25614319
pmcid: 7162685
Linsley PS, Speake C, Whalen E, Chaussabel D. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS ONE. 2014;9:e109760. https://doi.org/10.1371/journal.pone.0109760 .
doi: 10.1371/journal.pone.0109760
pubmed: 25314013
pmcid: 4196925
Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4:674–87. https://doi.org/10.1158/2159-8290.CD-13-0458 .
doi: 10.1158/2159-8290.CD-13-0458
pubmed: 24589924
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301–9. https://doi.org/10.1038/nm.3708 .
doi: 10.1038/nm.3708
pubmed: 25344738
Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–44. https://doi.org/10.1038/nrc.2016.14 .
doi: 10.1038/nrc.2016.14
pubmed: 26911188
Borden EC. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18:219–34. https://doi.org/10.1038/s41573-018-0011-2 .
doi: 10.1038/s41573-018-0011-2
pubmed: 30679806
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, et al. Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2020;38(500–515):e503. https://doi.org/10.1016/j.ccell.2020.08.005 .
doi: 10.1016/j.ccell.2020.08.005
Hubert M, Gobbini E, Couillault C, Manh TV, Doffin AC, Berthet J, Rodriguez C, Ollion V, Kielbassa J, Sajous C, et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.aav3942 .
doi: 10.1126/sciimmunol.aav3942
pubmed: 32303573
Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. IL-15 in the combination immunotherapy of cancer. Front Immunol. 2020;11:868. https://doi.org/10.3389/fimmu.2020.00868 .
doi: 10.3389/fimmu.2020.00868
pubmed: 32508818
pmcid: 7248178
Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F, Topalian SL. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7:305. https://doi.org/10.1186/s40425-019-0770-2 .
doi: 10.1186/s40425-019-0770-2
pubmed: 31730010
pmcid: 6858680
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52. https://doi.org/10.1016/j.immuni.2018.03.014 .
doi: 10.1016/j.immuni.2018.03.014
pubmed: 29562194
pmcid: 7116507
Forster F, Paster W, Supper V, Schatzlmaier P, Sunzenauer S, Ostler N, Saliba A, Eckerstorfer P, Britzen-Laurent N, Schutz G, et al. Guanylate binding protein 1-mediated interaction of T cell antigen receptor signaling with the cytoskeleton. J Immunol. 2014;192:771–81. https://doi.org/10.4049/jimmunol.1300377 .
doi: 10.4049/jimmunol.1300377
pubmed: 24337748
Lipnik K, Naschberger E, Gonin-Laurent N, Kodajova P, Petznek H, Rungaldier S, Astigiano S, Ferrini S, Sturzl M, Hohenadl C. Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice. Mol Med. 2010;16:177–87. https://doi.org/10.2119/molmed.2009.00172 .
doi: 10.2119/molmed.2009.00172
pubmed: 20454519
pmcid: 2864808
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55. https://doi.org/10.1016/s1471-4906(02)02302-5 .
doi: 10.1016/s1471-4906(02)02302-5
pubmed: 12401408
Reschke R, Gajewski TF. CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022;7:eabq6509. https://doi.org/10.1126/sciimmunol.abq6509 .
doi: 10.1126/sciimmunol.abq6509
pubmed: 35867802